Sola dosis facit venenum. Leukemia in gene therapy trials: A question of vectors, inserts and dosage?

Leukemia

Volumn 22, Issue 10, 2008, Pages 1849-1852

  Staal, F J T ^a   Pike Overzet, K ^a   Ng, Y Y ^a   van Dongen, J J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; INTERLEUKIN 2 RECEPTOR GAMMA; LENTIVIRUS VECTOR; MOLONEY LEUKEMIA ONCOVIRUS VECTOR; NOTCH1 RECEPTOR; ONCOPROTEIN; PROTEIN LMO2; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

5' UNTRANSLATED REGION; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER GENETICS; CELL FUNCTION; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; ENHANCER REGION; GENE DELETION; GENE DUPLICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INACTIVATION; GENE INSERTION; GENE NUMBER; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENOTOXICITY; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MOLONEY LEUKEMIA ONCOVIRUS; MONOGENIC DISORDER; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; NONVIRAL GENE THERAPY; PHENOTYPE; PRELEUKEMIA; PRIORITY JOURNAL; PROMOTER REGION; PROTO ONCOGENE; REVIEW; RISK ASSESSMENT; SOMATIC MUTATION; STEM CELL GENE THERAPY; T CELL LEUKEMIA; T CELL LYMPHOMA; TARGET CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

EID: 54049090008     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.219     Document Type: Review

References (40)

1. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
2. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302 415-419.
3. Howe S, Mansour M, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H et al. Insertional mutagenesis in combination with acquired somatic mutations leads to leukemogenesis following gene therapy of SCID-X1. J Clin Invest 2008, doi:10.1172/JC135798.
4. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest doi:10.1172/JC135700.
5. Baum C, von Kalle C, Staal FJ, Li Z, Fehse B, Schmidt M et al. Chance or necessity? Insertional mutagenesis in gene therapy and. its consequences. Mol Ther 2004, 9: 5-13.
6. Cavazzana-Calvo M, Fischer A. Gene therapy for severe combined immunodeficiency: Are we there yet? J Clin Invest 2007; 117: 1456-1465.
7. Gaspar HB, Thrasher AJ. Gene therapy for severe combined immunodeficiencies. Expert Opin Biol Ther 2005; 5: 1175-1182.
8. Pike-Overzet K, van der Burg M, Wagemaker G, van Dongen JJ, Staal FJ. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol Ther 2007; 15: 1910-1916.
9. Baum C, Dullmann J, Li Z, Fehse B, Meyer J, Williams DA et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101: 2099-2114.
10. Modlich U, Schambach A, Brugman MH, Wicke DC, Knoess S, Li Z et al Leukemia induction after a single retroviral vector insertion in Evil or Prdm16. Leukemia 2008; 22: 1519-1528.
11. Baum C. Insertional mutagenesis in gene therapy and stem cell biology. Curr Opin Hematol 2007; 14: 337-342.
12. Pike-Overzet K, de Ridder D, Weerkamp F, Baert MR, Verstegen MM, Brugman MH et al. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Leukemia 2007; 21: 754-763.
13. Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science 2004; 303: 333.
14. Woods NB, Bottero V, Schmidt M, von Kalle C, Verma IM. Gene therapy: therapeutic gene causing lymphoma. Nature 2006; 440: 1123.
15. Pike-Overzet K, de Ridder D, Weerkamp F, Baert MR, Verstegen MM, Brugman MH et al. Gene therapy: Is IL2RG oncogenic in T-cell development? Nature 2006; 443: E5; discussion E6-7.
16. Thrasher AJ, Gaspar HB, Baum C, Modlich U, Schambach A, Candotti F et al. Gene therapy: X-SCID transgene leukaemogenicity. Nature 2006; 443: E5-E6; discussion E6-7.
17. Shou Y, Ma Z, Lu T, Sorrentino BP. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci USA 2006; 103: 11730-11735.
18. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-696.
19. Modlich U, Bohne J, Schmidt M, von Kalle C, Knoss S, Schambach A et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108: 2545-2553.
20. Kustikova O, Fehse B, Modlich U, Yang M, Dullmann J, Kamino K et al Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005; 308: 1171-1174.
21. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497.
22. Thornhill SI, Schambach A, Howe SJ, Ulaganathan M, Grassman E, Williams D et al. Self- inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther 2008; 16: 590-598.
23. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003; 300: 1749-1751.
24. Trono D. Virology. Picking the right spot. Science 2003; 300 1670-1671.
25. De Palma M, Montini E, de Sio FR, Benedicenti F, Gentile A, Medico E et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 2005; 105: 2307-2315.
26. Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC et al Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004; 2: E234.
27. Lewinski MK, Yamashita M, Emerman M, Ciuffi A, Marshall H, Crawford G et al. Retroviral DNA integration: Viral and cellular determinants of target-site selection. PLoS Pathog 2006; 2: E60.
28. Deichmann A, Hacein-Bey-Abina S, Schmidt M, Garrigue A, Brugman MH, Hu J et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 2007; 117: 2225-2232.
29. Schwarzwaelder K, Howe SJ, Schmidt M, Brugman MH, Deichmann A, Glimm H et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 2007; 117: 2241-2249.
30. Aiuti A, Cassani B, Andolfi G, Mirolo M, Biasco L, Recchia A et al Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 2007; 117: 2233-2240.
31. Schmidt M, Carbonaro DA, Speckmann C, Wissler M, Bohnsack J, Elder M et al. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates. Nat Med 2003; 9: 463-468.
32. Schmidt M, Schwarzwaelder K, Bartholomae C, Zaoui K, Ball C, Pilz I et al. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods 2007; 4: 1051-1057.
33. Ng YY, van Kessel B, Lokhorst HM, Baert MR, van den Burg CM, Bloem AC et al. Gene-expression profiling of CD34+ cells from various hematopoietic stem-cell sources reveals functional differences in stem-cell activity. J Leukoc Biol 2004; 75: 314-323.
34. Zhong JF, Zhao Y, Sutton S, Su A, Zhan Y, Zhu L et al. Gene expression profile of murine long-term reconstituting vs short-term reconstituting hematopoietic stem cells. Proc Natl Acad Sci USA 2005; 102: 2448-2453.
35. Dik WA, Pike-Overzet K, Weerkamp F, de Ridder D, de Haas EF, Baert MR et al. New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. J Exp Med 2005; 201: 1715-1723.
36. Fehse B, Kustikova OS, Bubenheim M, Baum C. Pois(s)on - it's a question of dose. Gene Ther 2004; 11: 879-881.
37. Kustikova OS, Wahlers A, Kuhlcke K, Stahle B, Zander AR, Baum C et al Dose finding with retroviral vectors: Correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 2003; 102: 3934-3937.
38. Modlich U, Kustikova OS, Schmidt M, Rudolph C, Meyer J, Li Z et al Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005; 105: 4235-4246.
39. Ito M, Kobayashi K, Nakahata T. NOD/Shi-scid IL2rgamma(null) (NOG) mice more appropriate for humanized mouse models. Curr Top Microbiol Immunol 2008; 324: 53-76.
40. Pearson T, Greiner DL, Shultz LD. Humanized SCID mouse models for biomedical research. Curr Top Microbiol Immunol 2008; 324: 25-51.